Design of REACH: Phase 3 Randomized, Double-Blind, Placebo- Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD
Neuromuscular Disorders（2023）
关键词
losmapimod,fshd,efficacy,double-blind placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要